Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Income from Continuing Operations (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Income from Continuing Operations for 6 consecutive years, with 28453000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 26.81% to 28453000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 148344000.0 through Dec 2025, up 10.97% year-over-year, with the annual reading at 148125000.0 for FY2025, 0.66% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 28453000.0 at Caribou Biosciences, up from 29400000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 13159000.0 in Q1 2021, with the low at 47578000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 30217050.0, with a median of 29989000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations tumbled 664.48% in 2021, then soared 44.86% in 2023.
  • Over 5 years, Income from Continuing Operations stood at 18479000.0 in 2021, then plummeted by 65.47% to 30578000.0 in 2022, then decreased by 22.45% to 37442000.0 in 2023, then fell by 3.83% to 38875000.0 in 2024, then grew by 26.81% to 28453000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 28453000.0, 29400000.0, and 47578000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.